Display options
Cite
Hill BT, Kalaycio M. Profile of obinutuzumab for the treatment of patients with previously untreated chronic lymphocytic leukemia. Onco Targets Ther. 2015;8:2391-7doi: 10.2147/OTT.S68770.
Hill, B. T., & Kalaycio, M. (2015). Profile of obinutuzumab for the treatment of patients with previously untreated chronic lymphocytic leukemia. OncoTargets and therapy, 82391-7. https://doi.org/10.2147/OTT.S68770
Hill, Brian T, and Kalaycio, Matt. "Profile of obinutuzumab for the treatment of patients with previously untreated chronic lymphocytic leukemia." OncoTargets and therapy vol. 8 (2015): 2391-7. doi: https://doi.org/10.2147/OTT.S68770
Hill BT, Kalaycio M. Profile of obinutuzumab for the treatment of patients with previously untreated chronic lymphocytic leukemia. Onco Targets Ther. 2015 Aug 31;8:2391-7. doi: 10.2147/OTT.S68770. eCollection 2015. PMID: 26366093; PMCID: PMC4562745.
Copy Download .nbib Format: NLM
Share it on

Onco Targets Ther. 2015 Aug 31;8:2391-7. doi: 10.2147/OTT.S68770. eCollection 2015.

Profile of obinutuzumab for the treatment of patients with previously untreated chronic lymphocytic leukemia.

OncoTargets and therapy

Brian T Hill, Matt Kalaycio

Affiliations

  1. Department of Hematology and Medical Oncology, Taussig Cancer Institute, Cleveland Clinic, Cleveland, OH, USA.

PMID: 26366093 PMCID: PMC4562745 DOI: 10.2147/OTT.S68770

Abstract

Chronic lymphocytic leukemia (CLL) is a hematologic malignancy derived from a clonal population of mature B-lymphocytes characterized by relatively low CD20 antigen expression. Although the disease often takes an indolent course, the majority of patients will eventually require therapy. Standard treatment for medically fit patients includes purine analogs and/or alkylating agents in addition to the type I anti-CD20 monoclonal antibody, rituximab. This therapy is inherently myelosuppressive and can result in significant morbidity and even mortality in patients with impaired performance status due to age and/or medical comorbidities. Historically, treatment options for the elderly or frail patient population were limited to mono-therapy with the oral alkylating agent, chlorambucil, rituximab, or another type I anti-CD20 monoclonal antibody ofatumumab. Recently, a newer-generation anti-CD20 monoclonal antibody, obinutuzumab, was developed for patients with CLL. Obinutuzumab is a humanized type II monoclonal antibody that appears to have more direct antibody-dependent cell-mediated cytotoxicity (ADCC) and possibly more direct cytotoxicity in vitro than previously available type I antibodies. A large Phase III prospective randomized clinical trial for older patients with impaired renal function and/or significant medical comorbidities demonstrated that when compared to conventionally-dosed rituximab and chlorambucil, the combination of chlorambucil and obinutuzumab administered at a dose and schedule involving early loading doses improved response rates and progression-free survival without significantly increasing toxicity. Results of this pivotal trial led to the FDA (US Food and Drug Administration) approval of obinutuzumab in combination with chlorambucil for frontline treatment of CLL. Obinutuzumab expands the armamentarium of active and less-toxic targeted agents in the evolving treatment landscape of CLL, providing physicians and patients with an additional therapeutic option.

Keywords: CLL; cell-mediated cytotoxicity; chlorambucil; combination regimens; monoclonal antibody; obinutuzumab

References

  1. J Clin Oncol. 2001 Apr 15;19(8):2153-64 - PubMed
  2. Lancet. 2007 Jul 21;370(9583):230-9 - PubMed
  3. Am J Hematol. 2014 May;89(5):480-6 - PubMed
  4. Blood. 2003 Jan 1;101(1):6-14 - PubMed
  5. J Clin Oncol. 2013 Aug 10;31(23):2912-9 - PubMed
  6. N Engl J Med. 2000 Dec 14;343(24):1750-7 - PubMed
  7. Blood. 2004 Sep 15;104(6):1793-800 - PubMed
  8. Blood. 2007 Jan 15;109(2):405-11 - PubMed
  9. J Clin Oncol. 2010 Apr 1;28(10 ):1749-55 - PubMed
  10. J Clin Oncol. 2009 Sep 10;27(26):4378-84 - PubMed
  11. J Am Geriatr Soc. 1995 Feb;43(2):130-7 - PubMed
  12. MAbs. 2013 Nov-Dec;5(6):826-37 - PubMed
  13. J Clin Oncol. 2007 Dec 10;25(35):5616-23 - PubMed
  14. N Engl J Med. 2014 Mar 20;370(12):1101-10 - PubMed
  15. J Clin Oncol. 2005 Jun 20;23(18):4079-88 - PubMed
  16. J Clin Oncol. 2012 Sep 10;30(26):3209-16 - PubMed
  17. J Natl Cancer Inst Monogr. 2014 Aug;2014(48):41-51 - PubMed
  18. Blood. 2010 Jun 3;115(22):4393-402 - PubMed
  19. J Clin Oncol. 2007 Mar 1;25(7):793-8 - PubMed
  20. Blood. 2006 Feb 1;107(3):885-91 - PubMed
  21. Lancet. 2010 Oct 2;376(9747):1164-74 - PubMed
  22. Blood. 2009 Oct 15;114(16):3382-91 - PubMed
  23. Semin Hematol. 2010 Apr;47(2):107-14 - PubMed
  24. J Clin Oncol. 2013 Aug 10;31(23):2920-6 - PubMed
  25. Blood. 2013 Nov 14;122(20):3482-91 - PubMed
  26. Bull Cancer. 2007 Feb;94(2):198-202 - PubMed
  27. J Clin Oncol. 2014 Apr 20;32(12):1236-41 - PubMed
  28. J Clin Invest. 2009 Aug;119(8):2143-59 - PubMed
  29. MAbs. 2013 Jan-Feb;5(1):22-33 - PubMed

Publication Types